DB34442C-1882-495A-A2F0-2427116A1FAF
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 5.847568988173456
- age_years
- 66
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.605
- INTERFERON_ALPHA_RESPONSE+0.603
- IL6_JAK_STAT3_SIGNALING+0.593
- ALLOGRAFT_REJECTION+0.556
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.544
- ANGIOGENESIS+0.532
- TNFA_SIGNALING_VIA_NFKB+0.530
- APOPTOSIS+0.492
- INFLAMMATORY_RESPONSE+0.482
- G2M_CHECKPOINT+0.458
Top 10 suppressed
- KRAS_SIGNALING_DN-0.376
- SPERMATOGENESIS-0.287
- PANCREAS_BETA_CELLS-0.158
- BILE_ACID_METABOLISM+0.031
- MYOGENESIS+0.039
- HEME_METABOLISM+0.077
- FATTY_ACID_METABOLISM+0.133
- PEROXISOME+0.170
- XENOBIOTIC_METABOLISM+0.181
- ESTROGEN_RESPONSE_LATE+0.182
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C6A60028-2402-4048-90DF-F2B3712FB530 | — | — | 0.981 |
| 2 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.976 |
| 3 | SRR934750 | — | — | 0.976 |
| 4 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.974 |
| 5 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.973 |
| 6 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.973 |
| 7 | 44B1F003-553A-4C8A-A6AE-44C49262081C | — | — | 0.972 |
| 8 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.970 |
| 9 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.970 |
| 10 | 59B8FDC4-299D-45B9-9AC1-526B7ED652CE | — | — | 0.969 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 47 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.605 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.603 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.593 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.556 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.544 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.532 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| APOPTOSIS | 0.492 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.482 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.458 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.452 | Inavolisib | — uncovered |
| COMPLEMENT | 0.448 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.441 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.438 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.413 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.405 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.401 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.395 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.367 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.366 | Inavolisib | — uncovered |